Uses of antibodies directed against amyloid-β
Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
1. A method for treatment or delay of an amyloid beta-associated amyloidosis comprising administering a therapeutically effective amount of an antibody or a humanized form of said antibody to a subject in need thereof, wherein the antibody comprises
(i) a light chain comprising a variable part, the variable part of the light chain of said antibody comprising a polypeptide
(a) encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 53, SEQ ID NO: 57, and SEQ ID NO: 61 or
(b) having an amino acid sequence selected from the group consisting of SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 58, and SEQ ID NO: 62; or
(ii) a heavy chain comprising a variable part; the variable part of the heavy chain of said antibody comprising a polypeptide
(a) encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 51, SEQ ID NO: 55, SEQ ID NO: 59, and SEQ ID NO: 63 or
(b) having an amino acid sequence selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, and SEQ ID NO: 64.
2. The method of claim 1 , wherein said amyloidosis is a neurodegenerative disease selected from the group consisting of mild cognitive impairment, Alzheimer's disease and neurodegeneration in Down Syndrome.
3. The method of claim 1 , wherein said amyloidosis is sporadic Alzheimer's disease or a Familial Alzheimer's dementia.
4. The method of claim 3 , wherein said Familial Alzheimer's dementia is Familial British Dementia or Familial Danish Dementia.
5. The method according to claim 1 , wherein the antibody binds an Aβ peptide with a dissociation constant (KD) value of at least 10 −7 M.
6. The method according to claim 1 , wherein said antibody is a monoclonal antibody.
7. The method according to claim 1 , wherein:
the antibody comprises the light chain;
the light chain comprises the variable part; and
the variable part of the light chain of said antibody comprises the polypeptide encoded by the nucleotide sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 53, SEQ ID NO: 57 and SEQ ID NO: 61, or having the amino acid sequence selected from the group consisting of SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 58, and SEQ ID NO: 62.
8. The method according to claim 1 , wherein:
the antibody comprises the heavy chain;
the heavy chain comprises the variable part; and
the variable part of the heavy chain of said antibody comprises the polypeptide encoded by the nucleotide sequence selected from SEQ ID NO: 51, SEQ ID NO: 55, SEQ ID NO: 59 and SEQ ID NO: 63, or having the amino acid sequence selected from SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60 and SEQ ID NO: 64.
9. The method according to claim 1 , wherein:
the isolated antibody comprises the light chain;
the light chain comprises the variable part;
the variable part of the light chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 49 or having the amino acid sequence of SEQ ID NO: 50;
the isolated antibody comprises the heavy chain;
the heavy chain comprises the variable part; and
the variable part of the heavy chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 51, or having the amino acid sequence of SEQ ID NO: 52.
10. The method according to claim 1 , wherein:
the isolated antibody comprises the light chain;
the light chain comprises the variable part;
the variable part of the light chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 53 or having the amino acid sequence of SEQ ID NO: 54;
the isolated antibody comprises the heavy chain;
the heavy chain comprises the variable part; and
the variable part of the heavy chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 55, or having the amino acid sequence of SEQ ID NO: 56.
11. The method according to claim 1 , wherein:
the isolated antibody comprises the light chain;
the light chain comprises the variable part;
the variable part of the light chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 57 or having the amino acid sequence of SEQ ID NO: 58;
the isolated antibody comprises the heavy chain;
the heavy chain comprises the variable part; and
the variable part of the heavy chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 59, or having the amino acid sequence of SEQ ID NO: 60.
12. The method according to claim 1 , wherein:
the isolated antibody comprises the light chain;
the light chain comprises the variable part;
the variable part of the light chain of said antibody comprises the polypeptide encoded by the nucleotide sequence of SEQ ID NO: 61 or having the amino acid sequence of SEQ ID NO: 62;
the isolated antibody comprises the heavy chain;
the heavy chain comprises the variable part; and
a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 63, or having the amino acid sequence of SEQ ID NO: 64.
13. The method according to claim 1 , wherein said antibody is selected from the group consisting of:
Aβ 5-5-6 (Deposit No. DSM ACC 2923);
Aβ 6-1-6 (Deposit No. DSM ACC 2924);
Aβ 17-4-3 (Deposit No. DSM ACC 2925); and
Aβ 24-2-3 (Deposit No. DSM ACC 2926).
14. The method according to claim 1 , wherein said antibody is Aβ 6-1-6 (Deposit No. DSM ACC 2924).
15. The method according to claim 1 , wherein said antibody is Aβ 24-2-3 (Deposit No. DSM ACC 2926).
16. The method according to claim 1 , wherein said antibody is a humanized or chimeric antibody, or an antibody fragment.
17. The method according to claim 1 , wherein the antibody is a human antibody other than the variable part of the light chain and the variable part of the heavy chain.
18. The method according to claim 1 , wherein the antibody is a diabody or a single chain antibody.
19. The method according to claim 1 , wherein the antibody binds to an epitope of an antigen selected from the group consisting of:
pGlu-Aβ3-38;
pGlu-Aβ3-40;
pGlu-Aβ3-42; and
pGlu-Aβ3-x variants,
wherein x is an integer between 10 and 42.
20. The method according to claim 1 , wherein the antibody comprises a complementarity determining region that binds to an antigen selected from the group consisting of:
pGlu-Aβ3-38;
pGlu-Aβ3-40;
pGlu-Aβ3-42; and
pGlu-Aβ3-x variants,
wherein x is an integer between 10 and 42.
21. The method according to claim 1 , wherein the antibody is labeled.
22. The method according to claim 1 , wherein the antibody is obtained from any one of hybridoma cell lines DSM ACC 2923, DSM ACC 2924, DSM ACC 2925, or DSM ACC 2926.
23. The method according to claim 19 , wherein x is an integer between 18 and 42.
24. The method according to claim 19 , wherein x is an integer between 30 and 42.
25. The method according to claim 20 , wherein x is an integer between 18 and 42.
26. The method according to claim 20 , wherein x is an integer between 30 and 42.